Investornewsbreaks Nanoviricides (NYSE American: NNVC) Showcases NV-387'S Broad-Spectrum Antiviral Potential At Microcap Conference
NanoViricides, Inc. (NYSE American: NNVC) presented its latest advancements at the MicroCap <a target=_blank href= ...
BioPharma Dive3d
Model Medicines Unveils Generative AI, Multi-Modal Therapeutic Pipeline Breakthrough, Demonstrating End-To-End Drug Discovery Capabilities
Multi-Modal Models: A multi-modal discovery approach was implemented that engineered-in potency against the novel target and engineered-out a specific off-target interaction. The NCE library displayed ...
Investornewsbreaks Nanoviricides (NYSE American: NNVC) Partners With CRO To Advance NV-387 Antiviral Drug To Phase II Trials
NanoViricides, Inc. (NYSE American: NNVC) announced it has engaged a Clinical Research Organization (“CRO”) to conduct a Phase II clinical trial for ...
Ainos Achieves Major Breakthrough: Japan Patent Approval for VELDONA Redefines Antiviral Innovation
The global coronavirus therapeutics market is projected to exceed $16 billion by 2031. With its patented sublingual interferon technology, Ainos is poised to redefine antiviral treatment standards, ...
NanoViricides Engages CRO for Phase II Clinical Trial
NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum ...